# Longevity Health Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Longevity Health Holdings, Inc.). ## Overview Longevity Health Holdings, Inc. is a U.S.-based bio-aesthetics company focused on longevity and healthy aging. It develops and sells cosmetic skincare and haircare products for professional care providers and retail consumers, while also holding a pipeline of regenerative bone and tissue healing products that has been deprioritized. The company is also pursuing acquisitions and restructuring to concentrate on nearer-term commercial products. ## Products & services • Cosmetic skincare products based on Carmell Secretome™ • Haircare products for professional and retail use • Business-to-business cosmetic product sales • Direct-to-consumer cosmetic sales • Distributor channel sales • Regenerative bone and tissue healing product pipeline (paused R&D) - **Cosmetic skincare** (55%) — Skincare products aimed at skin health, longevity, and professional aesthetic use. - **Haircare** (20%) — Haircare products sold to support hair health through retail and professional channels. - **Direct-to-consumer sales** (10%) — Company-branded cosmetic products sold directly to end customers online or through owned channels. - **Distributor sales** (10%) — Third-party distribution of cosmetic products into broader retail and professional markets. - **Regenerative health pipeline** (5%) — Bone and tissue healing products and related R&D programs that are currently paused. - Cosmetic skincare products based on Carmell Secretome™ - Haircare products for professional and retail use - Business-to-business cosmetic sales - Direct-to-consumer sales - Distributor channel sales - Regenerative bone and tissue healing products (paused R&D) ## Customers The company sells primarily in the United States to professional care providers, retail consumers, and distributors. Its products are positioned for customers seeking cosmetic skincare and haircare solutions with a longevity and healthy-aging angle, rather than therapeutic medical treatments. Revenue is currently concentrated in commercial cosmetic products, while the regenerative pipeline is not the main near-term customer driver. - **Professional care providers** (primary) — Clinics and other professional users buy skincare and haircare products that meet technical performance requirements. - **Retail consumers** (primary) — End consumers buy branded cosmetic products for skin and hair health through direct channels. - **Distributors** (secondary) — Distribution partners buy products for resale and market reach expansion. - **Potential regenerative health partners** (emerging) — Future partners may license or commercialize paused bone and tissue healing programs. - Professional care providers buying products for aesthetic and skin-care use - Retail consumers seeking longevity and healthy-aging cosmetic products - Distributors reselling products into broader beauty and wellness channels - B2B customers that need technical product performance and consistency - Direct-to-consumer buyers attracted by branded skincare and haircare ## Geography The business is primarily U.S.-focused, with cosmetic product sales generated mainly in the United States. The company has not disclosed a broader international revenue footprint in the provided excerpts, so geographic exposure appears concentrated in one market. That concentration makes U.S. consumer demand, regulatory conditions, and channel execution especially important. - **United States** (100%) — Provided excerpts indicate cosmetic product sales are primarily in the U.S. - Primary revenue generation is in the United States - No disclosed country-level international revenue in the excerpts - U.S. concentration increases exposure to domestic consumer demand - Regulatory and product-approval activity is centered in the U.S. - Merger and licensing activity also appears U.S.-based ## Strategy Longevity is shifting toward nearer-term commercial cosmetic products and away from longer-dated research programs. Management is also pursuing acquisitions, including the Elevai acquisition and the THPlasma merger, to broaden product capabilities and support future growth. Cost reduction, channel commercialization, and liquidity preservation are central to the current strategy. - **Commercialize cosmetic skincare and haircare** (short-term) — These products have the clearest near-term revenue potential and support the company’s repositioning. - **Preserve liquidity and reduce operating burn** (short-term) — The company has negative working capital and operating cash outflows, so cash preservation is essential. - **Complete strategic acquisitions and integrations** (medium-term) — Acquisitions may add product rights, regulatory approvals, and commercial scale. - **Out-license non-core R&D programs** (medium-term) — Licensing can monetize paused programs without requiring heavy internal development spend. - Focus on cosmetic skincare and haircare with near-term commercial potential - Pause or de-emphasize longer-dated regenerative R&D programs - Expand commercialization through B2B, DTC, and distributor channels - Use acquisitions to add products, capabilities, and regulatory assets - Reduce costs and extend cash runway through restructuring ## Risks The company faces going-concern and liquidity risk because it has negative working capital, operating losses, and negative operating cash flow. Execution risk is elevated because the business is dependent on a small employee base, ongoing restructuring, and pending mergers that could be delayed or fail. As a consumer-facing cosmetics business, it also faces demand, channel, and product adoption risk, while the paused regenerative pipeline adds uncertainty around future monetization. - **Liquidity and going-concern pressure** [high] — The company reported negative working capital and negative operating cash flow, limiting flexibility. - **THPlasma merger completion risk** [high] — The merger is subject to closing conditions and litigation risk, and failure could hurt the strategic plan. - **Dependence on limited personnel** [medium] — The company disclosed only ten full-time employees, making retention critical. - **Commercial adoption risk for cosmetic products** [medium] — Revenue depends on continued launch and acceptance of skincare and haircare products. - Going-concern risk from negative working capital and cash burn - Merger failure or delay could disrupt strategy and consume management time - Small employee base increases execution and continuity risk - Consumer demand may not support planned cosmetic product growth - Paused R&D programs may never generate meaningful returns ## Accounting Investors should watch revenue recognition and gross-to-net deductions because the company disclosed discounts and allowances on product sales. Fair value measurements also matter, as prior periods included a large fair value change on a financing instrument, and merger accounting may introduce further valuation judgments. Going-concern disclosures, restructuring-related cost savings, and acquisition accounting can materially affect reported results and comparability. - **Revenue netting for discounts and allowances** — Gross-to-net deductions - **Fair value measurement of financing instruments** — Other expense and earnings volatility - **Going-concern assessment** — Liquidity disclosure and asset/liability measurement - **Acquisition accounting** — Balance sheet composition and future impairment risk - Gross revenue vs net revenue after discounts and allowances - Fair value changes on financing instruments can swing other expense - Acquisition accounting may affect goodwill and intangible assets - Going-concern assumptions affect asset and liability valuation - Restructuring and employee reductions affect expense comparability --- *Last updated: 2026-04-28T20:23:27.027400+00:00*